ArticleInternal and emergency medicine2026

Real-world lipid outcomes after switching PCSK9-targeting therapies in heterozygous familial hypercholesterolemia: the SHIFT-FH study.

Ilenia Lorenza Calcaterra et al.PubMed ↗Publisher ↗

No numbers read from the abstract.